2025-12-03 - Analysis Report
Okay, here's a comprehensive analysis of Transmedics Group Inc. (TMDX) based on the provided data:

**1) Return Rate Comparison & Alpha/Beta Analysis:**

*   **Company Overview:** Transmedics Group Inc. is a medical technology company focused on developing and delivering innovative organ care system (OCS) solutions for end-stage organ failure patients.
*   **Return Rate vs. S&P 500 (VOO):**
    *   TMDX Cumulative Return: 253.92%
    *   VOO Cumulative Return: 75.60%
    *   Divergence: 186.2 (Relative Divergence: 81.0)
    *   **Analysis:** TMDX has significantly outperformed the S&P 500, with a massive divergence in cumulative returns. The relative divergence of 81.0 suggests this outperformance is near the upper end of its historical range.
*   **Alpha/Beta Analysis:**

    | Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
    |------------|---------|-------|--------|------|--------|
    | 2019-2021  | -18.0%  | 83.5% | -61.0% | -0.0 | 0.7    |
    | 2020-2022  | 94.0%   | 83.5% | 95.0%  | 0.0  | 2.1    |
    | 2021-2023  | 65.0%   | 80.5% | 64.0%  | 0.1  | 2.7    |
    | 2022-2024  | 130.0%  | 85.5% | 109.0% | 0.1  | 2.1    |
    | 2023-2025  | 175.0%  | 85.5% | 110.0% | 0.3  | 4.9    |

    *   **Analysis:**
        *   **CAGR:** The Compound Annual Growth Rate shows strong growth in recent periods, particularly the last two years (2022-2024 and 2023-2025).
        *   **MDD:** The Maximum Drawdown is consistently high, indicating significant volatility and potential for losses.
        *   **Alpha:** The consistently positive Alpha suggests that TMDX has generated returns above what would be expected based on its beta, indicating strong performance relative to its risk.
        *   **Beta:** The low Beta values (close to zero) imply that the stock's price is not strongly correlated with the overall market. TMDX's performance is driven more by company-specific factors than broad market movements.
        *   **Cap:** Market Cap increased as well.

**2) Recent Stock Price Fluctuations:**

*   Current Close Price: 143.805
*   Last Market Data: Price: 143.905, Previous Close: 150.42, Change: -4.33
*   5-day SMA: 144.415
*   20-day SMA: 127.7788
*   60-day SMA: 121.398
*   **Analysis:** The price is currently below the 5-day SMA, suggesting a short-term downward trend.  The price is above both the 20-day and 60-day SMAs, indicating a longer-term uptrend. The recent price decrease (-4.33) indicates some recent selling pressure.

**3) RSI, PPO, and Market Risk Indicators:**

*   Market Risk Indicator (MRI): 0.9 (Medium Investment Recommended)
*   RSI: 66.68
*   PPO: 1.90
*   Hybrid Signal: "cash_0%_Buy 100% of cash (7 shares - Very Safe - MRI:0.90) Monthly invest 1.2% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)"
*   Recent (20 days) relative divergence change: 14.5 (+): 단기상승 (Short-term increase)
*   Expected Return (%): 30.0 (Expected excess return compared to S&P 500 if invested long-term)
*   **Analysis:**
    *   The MRI of 0.9 suggests a medium investment recommendation, balancing risk and potential return.
    *   The RSI of 66.68 is approaching overbought territory (typically above 70), suggesting the stock may be due for a pullback.
    *   The positive PPO indicates that the shorter-term moving average is above the longer-term moving average, confirming the uptrend.
    *   The Hybrid Signal is strongly bullish.
    *   The recent increase in relative divergence reinforces the recent short-term upward momentum.
    *   The expected return of 30% is significant, indicating analysts' positive outlook for the company's long-term growth.

**4) Recent News & Significant Events:**

*   **Positive Analyst Updates:** Morgan Stanley raised its price target, indicating continued confidence.
*   **Institutional Investment:** Quadrature Capital Ltd made a significant investment, signaling institutional interest.
*   **Valuation Discussions:** Articles are discussing TMDX's valuation after strong YTD gains, suggesting investors are assessing whether the stock is overvalued.
*   **Federal Reserve Impact:** News outlets are discussing the impact of Fed decisions on TMDX stock, demonstrating macro-economic factors being considered.
*   **Q3 Earnings Beat:** A previous article mentions TMDX beat Q3 earnings estimates.
*   **Stock Price Surge:** An article reports a 13% increase in stock price, highlighting a positive momentum shift.

**4-2) Analyst Opinions:**

*   Consensus: Buy (Mean: 1.67)
*   Number of Opinions: 11
*   Target Price: Average: $141.91, High: $170.00, Low: $114.00
*   Recent Rating Changes: No changes reported

**5) Comprehensive Analysis:**

TMDX has demonstrated significant outperformance compared to the S&P 500, driven by company-specific factors rather than broad market trends. The company has strong growth (high CAGR), but also significant volatility (high MDD). Analyst opinions are generally positive, with a "Buy" consensus and a target price range that suggests further upside potential, despite a small downtick in price.

Recent news highlights positive analyst updates and institutional investment, supporting a bullish outlook. However, investors are also examining the stock's valuation, suggesting some caution may be warranted. The MRI indicates a medium investment recommendation, while the RSI approaching overbought territory suggests the stock may be due for a correction.

**Overall:**

TMDX appears to be a high-growth stock with strong potential, but also carries significant risk due to its volatility. The analyst consensus and recent news suggest a positive outlook. Investors should be aware of the potential for price swings and carefully consider their risk tolerance before investing. The recent price decrease is a possible concern, but seems to be a small downtick compared to the overall growth.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.